Abstract
Multiple endocrine neoplasia type 2 is an inherited cancer syndrome characterized by tumors of thyroid and adrenal tissues. Germline mutations of the REarranged during Transfection (RET) proto-oncogene, leading to its unregulated activation, are the underlying cause of this disease. Multiple endocrine neoplasia type 2 has been a model in clinical cancer genetics, demonstrating how knowledge of the genetic basis can shape the diagnosis and treatment of the disease. Here, we discuss the nature and effects of the most common recurrent mutations of RET found in multiple endocrine neoplasia type 2. Current understanding of the molecular mechanisms of RET mutations and how they alter the structure and function of the RET protein leading to its aberrant activation, and the effects on RET localization and signaling are described.
Citations
Jul 1, 2015·Molecular and Cellular Endocrinology·Charlotte Lepoutre-LusseyJudith Favier
Jan 31, 2016·Anti-cancer Drugs·Dale R MilesLinh T Nguyen
Aug 8, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Antonella VerrientiRocco Bruno
Jul 12, 2016·Pediatric Dermatology·Francisco AlcántaraRaúl De Lucas
Oct 23, 2013·PloS One·Lauren M Wagner, Neal A DeLuca
Feb 11, 2018·Cell and Tissue Research·Charlotte Lussey-LepoutreJudith Favier
Dec 18, 2013·Molecular BioSystems·C George Priya DossMaitreya Das
May 23, 2014·Journal of Biosciences·Xiao-Ping QiRen-Rong Yang
Mar 3, 2015·Endocrine·A L SilvaM J Bugalho
Oct 31, 2012·International Journal of Molecular Sciences·Ke MaZheng Li
Jun 10, 2016·Molecular Medicine Reports·Rongbiao Ying, Jun Feng
Oct 22, 2020·Familial Cancer·Josep OriolaJosefina Biarnés
Jun 13, 2021·The Lancet. Diabetes & Endocrinology·Vivek SubbiahMatthew H Taylor
Aug 24, 2021·Frontiers in Oncology·Qiu-Shi ZhuangPeter E Lobie